CSIMarket
 
Enlivex Therapeutics Ltd   (ENLV)
Other Ticker:  
 
 
Price: $4.1800 $0.07 1.703%
Day's High: $4.27 Week Perf: 0.24 %
Day's Low: $ 3.95 30 Day Perf: 30.22 %
Volume (M): 91 52 Wk High: $ 4.37
Volume (M$): $ 380 52 Wk Avg: $2.50
Open: $4.19 52 Wk Low: $1.20



 Market Capitalization (Millions $) 77
 Shares Outstanding (Millions) 18
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -31
 Cash Flow (TTM) (Millions $) 39
 Capital Exp. (TTM) (Millions $) 8

Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd is a clinical-stage biotechnology company that focuses on developing novel therapies for immune system disorders. The company is known for its flagship product, Allocetra, which is a cell-based immunotherapy designed to rebalance the immune system and restore its proper function.

Enlivex's approach is based on the understanding that many diseases, such as sepsis, graft-versus-host disease, and solid tumors, result from an imbalance in the immune system. Allocetra addresses this imbalance by selectively targeting excessive immune responses while leaving the beneficial immune functions intact.

The company has conducted several clinical trials to evaluate the safety and efficacy of Allocetra in various indications. The results have shown promising outcomes, leading to collaborations with leading medical centers and biopharmaceutical companies.

Enlivex is committed to advancing its product pipeline and developing innovative therapies to address unmet medical needs. The company is driven by the goal of improving patients' quality of life and transforming the management of immune system disorders.


   Company Address: 14 Einstein Street Ness Ziona 7403618
   Company Phone Number: 2.6208072   Stock Exchange / Ticker: NASDAQ ENLV
   ENLV is expected to report next financial results on April 09, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Enlivex's Novel Immunotherapy, Allocetra, Receives Regulatory Authorization for Phase I/II Trial in Knee Osteoarthritis Patients

Published Wed, Jan 17 2024 1:00 PM UTC

Enlivex Receives IMOH Regulatory Authorization for a Phase I/II Trial Evaluating Allocetra in Knee Osteoarthritis PatientsEnlivex Therapeutics Ltd., a clinical-stage macrophage reprogramming immunotherapy company, has received authorization from the Israeli Ministry of Health (IMOH) to initiate a multi-country, double-blind, randomized, placebo-controlled Phase I/II trial. T...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com